We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Letermovir

News List

NICE recommends Prevymis on the NHS after re-evaluation europeanpharmaceuticalreview
June 05, 2019
The National Institute for Health and Care Excellence is recommending MSD’s Prevymis (letermovir) within the NHS.
Merck gears up to file antiviral letermovir in the US, EU pharmatimes
February 28, 2017
Merck & Co said it is planning to submit regulatory applications for letermovir in the US and European Union sometime this year, on the back of late-stage data showing its promise in preventing a serious viral infection in patients undergoing a bone marro
Merck’s Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) In firstwordpharma
February 27, 2017
Letermovir Prophylaxis Associated with Lower All-Cause Mortality Through Week 24 Post-Transplant. Company Plans to Submit New Drug Applications for Letermovir in U.S. and EU in 2017.